ESMO Congress 2026Developing

PSMA-617

7 reports3 sourcesupdated 6 hours ago

Start here

No synthesis yet — start with the coverage timeline below.

Coverage timeline

Follow the coverage to see the different angles.

Oct 25

06:22
x.com
#ESMO26 TiP

Oct 24

00:30
x.com
Re-LuPSMA: Interim Safety Analysis of the Prospective Phase II Trial of 177Lu-PSMA-617 Retreatment in #mCRPC. Presented by Johanna Enke, MD, #ESMO26 written coverage by @zklaassen_

Oct 23

23:45
x.com
ctDNA as Correlates of Intrinsic and Acquired Resistance to 177Lu-PSMA-617 in #mCRPC. Presented by @aloktewar @DanaFarber. #ESMO26 written coverage by @chavarriagaj @PSH_Urology &g
22:25
x.com
Re-LuPSMA: Interim Safety of a Ph II Trial of 177Lu-PSMA-617 Retreatment in mCRPC @urotoday #ESMO26 @CalaisJeremie
21:20
medicalxpress.com
Real-world results confirm benefit of antigen therapy for prostate cancer

Oct 21

17:40
mp.weixin.qq.com

Oct 20

22:48
mp.weixin.qq.com

Heat trend for this story

Heat now 20·Peak in the comparable set 31 (Oct 24 01:00)·Change over 24h in the comparable set -13%·Participants now 6

Participants counted6

Heat over time

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.